Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer
Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer
Combination of pazopanib and paclitaxel safe in urothelial cancer
Tackling renal cancer with a combination of autologous immunotherapy and sunitinib
Challenging results from mTOR inhibitors in metastatic clear cell renal cancer
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction
mRCC: Real-world experience: achieving efficacy beyond clinical trials
mRCC: Are we doing all we can to manage adverse events?
mRCC: Understanding the patient's perspective
mRCC: Panel discussion
mRCC: Closing remarks
Optimizing survival in advanced prostate cancer: Welcome and introduction
Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices